JP6663012B2 - 構造記憶特性を有する細胞増殖用足場の製造方法 - Google Patents
構造記憶特性を有する細胞増殖用足場の製造方法 Download PDFInfo
- Publication number
- JP6663012B2 JP6663012B2 JP2018530120A JP2018530120A JP6663012B2 JP 6663012 B2 JP6663012 B2 JP 6663012B2 JP 2018530120 A JP2018530120 A JP 2018530120A JP 2018530120 A JP2018530120 A JP 2018530120A JP 6663012 B2 JP6663012 B2 JP 6663012B2
- Authority
- JP
- Japan
- Prior art keywords
- matrix material
- tissue matrix
- scaffold
- decellularized tissue
- decellularized
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000010261 cell growth Effects 0.000 title claims description 35
- 238000004519 manufacturing process Methods 0.000 title claims description 19
- 239000011159 matrix material Substances 0.000 claims description 120
- 210000001519 tissue Anatomy 0.000 claims description 112
- 239000000463 material Substances 0.000 claims description 58
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 36
- 239000000243 solution Substances 0.000 claims description 28
- 102000008186 Collagen Human genes 0.000 claims description 23
- 108010035532 Collagen Proteins 0.000 claims description 23
- 229920001436 collagen Polymers 0.000 claims description 23
- 239000002245 particle Substances 0.000 claims description 23
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 21
- 239000000725 suspension Substances 0.000 claims description 21
- 239000000017 hydrogel Substances 0.000 claims description 20
- 210000003491 skin Anatomy 0.000 claims description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 11
- 238000007710 freezing Methods 0.000 claims description 11
- 239000002994 raw material Substances 0.000 claims description 11
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 10
- 230000008014 freezing Effects 0.000 claims description 10
- 230000020477 pH reduction Effects 0.000 claims description 10
- 239000000835 fiber Substances 0.000 claims description 9
- 239000011780 sodium chloride Substances 0.000 claims description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 8
- 241001465754 Metazoa Species 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 230000007935 neutral effect Effects 0.000 claims description 8
- 239000012670 alkaline solution Substances 0.000 claims description 7
- 230000005855 radiation Effects 0.000 claims description 7
- 102000004190 Enzymes Human genes 0.000 claims description 6
- 108090000790 Enzymes Proteins 0.000 claims description 6
- 229960003964 deoxycholic acid Drugs 0.000 claims description 6
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 claims description 6
- 238000005406 washing Methods 0.000 claims description 6
- 239000002202 Polyethylene glycol Substances 0.000 claims description 5
- 210000000845 cartilage Anatomy 0.000 claims description 5
- 230000004663 cell proliferation Effects 0.000 claims description 5
- 238000005520 cutting process Methods 0.000 claims description 5
- 210000003041 ligament Anatomy 0.000 claims description 5
- 229920001223 polyethylene glycol Polymers 0.000 claims description 5
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 5
- 210000002435 tendon Anatomy 0.000 claims description 5
- 210000004204 blood vessel Anatomy 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 210000002429 large intestine Anatomy 0.000 claims description 4
- 230000005499 meniscus Effects 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 238000005498 polishing Methods 0.000 claims description 4
- 210000000813 small intestine Anatomy 0.000 claims description 4
- 238000004659 sterilization and disinfection Methods 0.000 claims description 4
- 210000002784 stomach Anatomy 0.000 claims description 4
- 210000003708 urethra Anatomy 0.000 claims description 4
- 239000000644 isotonic solution Substances 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- ZPIRTVJRHUMMOI-UHFFFAOYSA-N octoxybenzene Chemical compound CCCCCCCCOC1=CC=CC=C1 ZPIRTVJRHUMMOI-UHFFFAOYSA-N 0.000 claims description 3
- 238000004806 packaging method and process Methods 0.000 claims description 3
- 210000003932 urinary bladder Anatomy 0.000 claims description 3
- 238000010894 electron beam technology Methods 0.000 claims description 2
- 210000000188 diaphragm Anatomy 0.000 claims 1
- 210000000944 nerve tissue Anatomy 0.000 claims 1
- 238000010257 thawing Methods 0.000 claims 1
- 239000000515 collagen sponge Substances 0.000 description 16
- 238000010382 chemical cross-linking Methods 0.000 description 12
- 238000004925 denaturation Methods 0.000 description 8
- 230000036425 denaturation Effects 0.000 description 8
- 230000004071 biological effect Effects 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- 210000004872 soft tissue Anatomy 0.000 description 6
- 239000002131 composite material Substances 0.000 description 5
- 230000007547 defect Effects 0.000 description 5
- 210000004207 dermis Anatomy 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 229920001661 Chitosan Polymers 0.000 description 4
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 4
- 206010052428 Wound Diseases 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000000227 grinding Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 102000000503 Collagen Type II Human genes 0.000 description 3
- 108010041390 Collagen Type II Proteins 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 229920001222 biopolymer Polymers 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000007515 enzymatic degradation Effects 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 230000005251 gamma ray Effects 0.000 description 3
- 238000001757 thermogravimetry curve Methods 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 229920002385 Sodium hyaluronate Polymers 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 238000010306 acid treatment Methods 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 206010061592 cardiac fibrillation Diseases 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000003431 cross linking reagent Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 2
- XNNBBRKQMUTIKD-UHFFFAOYSA-L disodium;2-[2-[carboxylatomethyl(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetate;phosphoric acid Chemical compound [Na+].[Na+].OP(O)(O)=O.OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O XNNBBRKQMUTIKD-UHFFFAOYSA-L 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- 230000002600 fibrillogenic effect Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 210000004209 hair Anatomy 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- -1 polypropylene Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 229940010747 sodium hyaluronate Drugs 0.000 description 2
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 210000004003 subcutaneous fat Anatomy 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 238000012424 Freeze-thaw process Methods 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 210000002777 columnar cell Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 238000002682 general surgery Methods 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000021368 organ growth Effects 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
- A61L27/3687—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by the use of chemical agents in the treatment, e.g. specific enzymes, detergents, capping agents, crosslinkers, anticalcification agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L27/44—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
- A61L27/48—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with macromolecular fillers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/24—Collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
- A61L27/3691—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by physical conditions of the treatment, e.g. applying a compressive force to the composition, pressure cycles, ultrasonic/sonication or microwave treatment, lyophilisation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/52—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/56—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/58—Materials at least partially resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/16—Materials with shape-memory or superelastic properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
- A61L27/3608—Bone, e.g. demineralised bone matrix [DBM], bone powder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
- A61L27/3612—Cartilage, synovial fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
- A61L27/3616—Blood, e.g. platelet-rich plasma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
- A61L27/362—Skin, e.g. dermal papillae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
- A61L27/3629—Intestinal tissue, e.g. small intestinal submucosa
Description
屠殺して脱毛した直後の豚から新鮮な皮を収集し、皮下脂肪と表皮を機械的に除去し、厚さが約1.5ミリメートルの真皮を取る。皮膚中の血液とほかの汚れを洗浄し、皮膚上に残った毛を手動で抜く。豚の真皮を約1cm角の小塊に切断し、精製水できれいに洗浄する。200グラムの真皮原料を秤量して1リットルの高密度ポリプロピレンフラスコに入れ、2%の炭酸ナトリウム及び10mMの水酸化ナトリウムを含有するアルカリ溶液を800ミリリットル添加し、振動テーブルで20時間処理する(pH=12.5)。アルカリ溶液で処理した後、0.5Mの酢酸溶液で中和させる。中和後の溶液を除去し、0.5%のデオキシコール酸ナトリウムと5mMのエチレンジアミン四酢酸二ナトリウムとを含有する5mMの2−[4−(2−ヒドロキシエチル)−1−ピペラジニル]エタンスルホン酸緩衝液(pH=7.5)を800ミリリットル添加し、室温下で、振動テーブルで一晩(約20時間)処理して脱細胞化する。脱細胞化処理された小塊の真皮材料を無菌生理食塩水で2回迅速に洗い流し、各回が30〜60分間である。小塊の真皮材料を高速研磨機で研磨し、細かい脱細胞化組織マトリックス材料を製造し、組織粒子の平均幅を500〜2000ミクロンの間とし、長さを2000〜5000ミクロンの間とする。遠心法でマトリックス材料を収集し、上澄みを除去する。無菌生理食塩水を添加し、遠心沈降したマトリックス材料を懸濁させ、さらにマトリックス材料を遠心洗浄する。0.1%の過酢酸溶液を800ミリリットル添加し、60分間処理する。マトリックス材料を遠心処理して収集する。無菌生理食塩水を用い、懸濁、振動、遠心処理及び収集を行い、マトリックス材料を2回洗浄し、各回が30〜60分間である。マトリックス材料50グラムあたりに10mMのエチレンジアミン四酢酸二ナトリウムリン酸塩緩衝溶液(pH=7.5)を500ミリリットル添加し、高速研磨機で研磨して粉砕し、微繊維状又は絮状の脱細胞化組織マトリックス材料を製造し、微繊維の直径を2〜250ミクロンの間、長さを100〜3000ミクロンの間とする。遠心処理して、上澄みを除去し、遠心沈降したマトリックス微繊維材料を収集する。微繊維状又は絮状のマトリックス材料を0.9%の塩水に懸濁させ、細胞外組織マトリックス材料の懸濁液を得て、懸濁液における微繊維マトリックス材料の含有量が4.9%である。次に微繊維状又は絮状のマトリックス材料の一部を取り、酢酸を添加し、最終的な酢酸濃度を50mMとする。酸性化処理によって、マトリックス材料を膨張させた後、高速研磨機で継続的に研磨し、大きさが10〜250ミクロンのヒドロゲル粒子を製造し、酸性化されたヒドロゲルのpHを水酸化ナトリウム溶液で6.5に調整し、ヒドロゲル材料の含有量が1.5%である。微繊維状又は絮状の組織マトリックス材料と酸性化処理されたヒドロゲル状の組織マトリックス材料とを乾燥重量比70%:30%で混合する。混合後のマトリックス材料の懸濁液を円板状と円筒状の金型に注入し、−20℃の冷蔵庫に入れて凍結する。氷結によって多孔質構造を形成する。凍結後、25kGyでγ線放射処理を行い、構造記憶特徴を有する安定した細胞増殖用足場を得て、室温下で保存できる。
屠殺して脱毛した直後の豚から新鮮な皮を収集し、皮下脂肪と表皮を除去し、皮膚中の血液とほかの汚れを洗浄し、皮膚上に残った小さな毛を手動で抜いた後、豚の真皮を厚さが約2ミリメートル、幅が1cm角の小塊に切断し、精製水で1回洗浄し、原料を200グラム秤取し、高密度ポリプロピレンフラスコに入れる。アルカリ液(2%の炭酸ナトリウム、10mMの水酸化ナトリウム及び0.2%のポリエチレングリコールオクチルフェニルエーテルを含有する)を添加し、振動テーブルに置いて、アルカリ溶液で20時間処理する。酢酸溶液を添加して中和させる。0.5%のドデシル硫酸ナトリウム(5mMのエチレンジアミン四酢酸二ナトリウム及び5mMの2−[4−(2−ヒドロキシエチル)−1−ピペラジニル]エタンスルホン酸緩衝液に溶解する)を添加して脱細胞化し、室温下で、振動テーブルで20時間振動処理する。無菌生理食塩水で2回迅速に洗い流し、各回が30〜60分間である。材料を高速研磨機で、長さが約2.0〜4.0mm、幅が約0.5〜2.0mmになるまで研磨して粉砕する。遠心処理して、マトリックス材料を収集し、上澄みを除去する。収集したマトリックス材料を0.1%の過酢酸溶液に浸漬して2時間処理する。無菌生理食塩水で1〜2回洗い流し、各回が30〜60分間である。生理食塩水で洗い流された材料を10mMのエチレンジアミン四酢酸二ナトリウムリン酸塩緩衝溶液で洗浄し、高速研磨機で、長さが約500〜2500ミリメートル、幅が約50〜500ミリメートルになるまで研磨して粉砕し、遠心処理して、マトリックス微繊維を収集し、上澄みを除去する。マトリックス微繊維を0.9%の塩水中に懸濁させ、細胞外組織マトリックス微繊維材料の懸濁液を得て、材料含有量が4.6%である。三分の一の微繊維材料の懸濁液を取り、50mMの酢酸溶液で材料を希釈し酸性化する。酸性化処理された材料を高速研磨機で研磨して粉砕し、ヒドロゲル材料に製造する。酸性化されたヒドロゲル材料を水酸化ナトリウム溶液で中和させ、pHを6.5に調整し、得たヒドロゲル材料の含有量が1.7%である。微繊維状又は絮状の組織マトリックス材料と酸性化されたヒドロゲル材料とを乾燥重量比80%:20%で混合し、混合後のマトリックス材料を金型に注入する。−20℃の冷凍庫で凍結した後、25kGyでγ線放射処理を行い、生体組織細胞増殖用の足場を得る。図4に示すように、示差走査熱量計(DSC)で以下の材料の熱安定性能を比較し測定した。(A)は0.5%のドデシル硫酸ナトリウムで脱細胞化された微繊維状又は絮状の組織マトリックス材料、(B)は酸性化処理されたヒドロゲル状組織マトリックス材料、(C)は乾燥重量比で80%の微繊維状の脱細胞化組織マトリックス材料と20%の酸性化処理されたヒドロゲル状粒子で製造してなる細胞増殖用足場を示す。0.5%のドデシル硫酸ナトリウムで脱細胞化された微繊維状又は絮状の組織マトリックス材料は初期変性温度が53.1℃であり、エンタルピーが−49.2J/gdwであり、酸性化処理されたヒドロゲル状組織マトリックス材料は初期変性温度が34.9℃であり、エンタルピーが−30.2J/gdwであり、最終的に製造された細胞増殖用足場は初期変性温度が53.3℃であり、エンタルピーが−50.3J/gdwであり、天然の豚の真皮の細胞外マトリックス材料の安定性をほぼ保持する。
Claims (4)
- 脱細胞化組織マトリックス材料を製造するための生体組織原料を収集し、前記原料は、動物の皮膚、軟骨、血管、半月板、胃、小腸、大腸、隔膜、腱、靭帯、神経組織、膀胱及び尿道を含むがそれらに限定されず、コラーゲンを含有する組織を切断して分離し、1〜20ミリメートルの小塊又は小片に切断する原料収集のステップ1と、
ステップ1で得た小塊又は小片を2%の炭酸ナトリウムで4〜48時間浸漬し又はpHが10.5〜12.5のほかのアルカリ性溶液で浸漬する原料消毒のステップ2と、
ステップ2で浸漬した小塊又は小片を、0.1〜2.0%のデオキシコール酸ナトリウム、ポリエチレングリコールオクチルフェニルエーテル又は10〜200単位/リットルの中性酵素で4〜36時間脱細胞化処理する脱細胞化処理のステップ3と、
ステップ3で脱細胞化処理された小塊又は小片を、材料1キログラムあたり1〜6リットルの生理食塩水又はほかの中性等浸透圧溶液で2〜5回洗浄し、各回が1〜12時間である脱細胞化組織マトリックス材料の洗浄のステップ4と、
ステップ4で洗浄された脱細胞化組織マトリックス材料の小塊又は小片を粉砕機で微繊維状又は絮状の脱細胞化組織マトリックス材料に粉砕して研磨する脱細胞化組織マトリックスの粉砕のステップ5と、
ステップ5で得た微繊維状又は絮状の脱細胞化組織マトリックス材料の一部を、pHが2.8〜3.5の塩酸又は酢酸溶液5〜200mMに浸漬して1〜24時間酸性化処理し、さらにマトリックス材料をヒドロゲル状粒子に粉砕して研磨し、水酸化ナトリウム溶液でpHを4.0〜6.5に調節する酸性化処理のステップ6と、
20〜30℃の室温で、60〜90%の比率で、微繊維状又は絮状の脱細胞化組織マトリックス材料と40%〜10%で酸性化処理されたヒドロゲル状の脱細胞化組織マトリックス粒子とを均一に混合して包装金型に注入する混合及び金型注入のステップ7と、
脱細胞化組織マトリックス材料の懸濁液を収容した金型を−20℃以下の冷凍庫に入れて冷凍し、又は1回目解凍した後に再冷凍することによりその懸濁液のギャップ構造を向上させる凍結処理のステップ8と、
冷凍した材料をX−線、γ線又は電子線で処理する放射処理のステップ9と、
ステップ9で処理された脱細胞化組織マトリックス材料を、常温下で保存可能な多孔質細胞増殖用足場に製造するステップ10と、を含み、前記動物にはヒトが含まれないことを特徴とする構造記憶特性を有する細胞増殖用足場の製造方法。 - 前記ステップ10では、多孔質細胞増殖用足場の脱細胞化組織マトリックス材料は繊維直径が2〜250ミクロン、長さが100〜3000ミクロンの微繊維状又は絮状の脱細胞化組織マトリックス材料、及び粒子直径が2〜150ミクロンの酸性化処理されたヒドロゲル状の脱細胞化組織マトリックス材料であることを特徴とする請求項1に記載の構造記憶特性を有する細胞増殖用足場の製造方法。
- マトリックス材料は、脱細胞化組織マトリックス材料の総含有量が10〜100mg/cm3であり、細胞増殖用足場の全ギャップ率が90〜99%であり、口径の25ミクロンより大きいギャップ率が80〜98%であることを特徴とする請求項2に記載の構造記憶特性を有する細胞増殖用足場の製造方法。
- 前記足場では、微繊維状又は絮状の脱細胞化組織マトリックス材料は乾燥重量比で60%〜90%であり、前記酸性化処理されたヒドロゲル状の脱細胞化組織マトリックス材料は乾燥重量比で40%〜10%であることを特徴とする請求項2に記載の構造記憶特性を有する細胞増殖用足場の製造方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510986265.8 | 2015-12-25 | ||
CN201510986265.8A CN106913907B (zh) | 2015-12-25 | 2015-12-25 | 一种具有结构记忆特性的细胞生长支架的制备方法 |
PCT/CN2016/111926 WO2017107997A1 (zh) | 2015-12-25 | 2016-12-24 | 一种具有结构记忆特性的细胞生长支架的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2018537982A JP2018537982A (ja) | 2018-12-27 |
JP6663012B2 true JP6663012B2 (ja) | 2020-03-11 |
Family
ID=59089086
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018530120A Active JP6663012B2 (ja) | 2015-12-25 | 2016-12-24 | 構造記憶特性を有する細胞増殖用足場の製造方法 |
Country Status (9)
Country | Link |
---|---|
US (1) | US10814037B2 (ja) |
EP (1) | EP3369439B1 (ja) |
JP (1) | JP6663012B2 (ja) |
CN (1) | CN106913907B (ja) |
ES (1) | ES2763799T3 (ja) |
HU (1) | HUE048391T2 (ja) |
PL (1) | PL3369439T3 (ja) |
PT (1) | PT3369439T (ja) |
WO (1) | WO2017107997A1 (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR102018003726B1 (pt) * | 2018-02-26 | 2023-04-11 | Universidade Federal Do Espírito Santo - Ufes | Método de produção de um biomaterial ósseo, biomaterial ósseo e uso do mesmo |
KR102411248B1 (ko) * | 2019-06-21 | 2022-06-21 | 주식회사 에스앤지바이오텍 | 무세포화 처리방법 |
WO2021034925A1 (en) * | 2019-08-21 | 2021-02-25 | Lifecell Corporation | Fixed-shape tissue matrix and related methods |
CN111671974A (zh) * | 2020-04-26 | 2020-09-18 | 上海亚朋生物技术有限公司 | 一种吸水诱导形状记忆性的脱细胞真皮基质组织填充物及其制备方法 |
WO2022138992A1 (ko) * | 2020-12-21 | 2022-06-30 | 주식회사 엘앤씨바이오 | 무세포 신경 이식재 및 그 제조방법 |
CN117205373B (zh) * | 2023-11-08 | 2024-02-02 | 独步吾奇生物医疗科技(江苏)有限公司 | 一种胶原支架及其制备方法和应用 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2943520C2 (de) * | 1979-10-27 | 1982-05-19 | Fa. Carl Freudenberg, 6940 Weinheim | Verfahren zur Herstellung von Kollagenschwamm für medizinische oder kosmetische Zwecke |
US6206931B1 (en) * | 1996-08-23 | 2001-03-27 | Cook Incorporated | Graft prosthesis materials |
JP5226914B2 (ja) * | 1998-06-19 | 2013-07-03 | ライフセル コーポレイション | 粒状無細胞組織マトリックス |
EP1207819B1 (en) * | 1999-08-06 | 2009-03-04 | Cook Biotech, Inc. | Tubular graft construct |
CN1235947C (zh) * | 2001-09-10 | 2006-01-11 | 王由 | 胶原纤维的提取方法和用其制造组织填充剂的方法 |
US8221780B2 (en) * | 2004-04-20 | 2012-07-17 | Depuy Mitek, Inc. | Nonwoven tissue scaffold |
DK3473260T3 (da) * | 2007-07-10 | 2020-12-21 | Lifecell Corp | Acellulære vævsmatrixs-sammensætninger til vævsreparation |
AU2009281937B2 (en) * | 2008-08-14 | 2015-05-07 | 3M Innovative Properties Company | Tissue scaffolds |
CN101507831B (zh) * | 2009-03-25 | 2012-12-26 | 北京大清生物技术有限公司 | 一种促进手术伤口愈合的材料及其制备方法 |
GB0912399D0 (en) * | 2009-07-16 | 2009-08-26 | Ucl Business Plc | Polymeric collagen biomaterials |
US8784499B2 (en) * | 2010-03-25 | 2014-07-22 | Lifecell Corporation | Preparation of regenerative tissue scaffolds |
CA3054722A1 (en) * | 2010-07-08 | 2012-01-12 | Lifecell Corporation | Method for shaping tissue matrices |
EP2696908B1 (en) * | 2011-04-14 | 2015-03-11 | Lifecell Corporation | Regenerative materials |
ES2729712T3 (es) * | 2011-12-20 | 2019-11-05 | Lifecell Corp | Productos de tejido de lámina |
JP6100702B2 (ja) * | 2012-01-12 | 2017-03-22 | 株式会社ニッピ | コラーゲン構造体、およびコラーゲン構造体の製造方法 |
CA2911592C (en) * | 2013-05-07 | 2021-10-26 | The Chemo-Sero-Therapeutic Research Institute | Hybrid gel comprising particulate decellularized tissue |
CA2919374C (en) * | 2013-07-30 | 2019-12-03 | Musculoskeletal Transplant Foundation | Acellular soft tissue-derived matrices and methods for preparing same |
CN103432627B (zh) * | 2013-08-26 | 2015-03-25 | 北京瑞健高科生物科技有限公司 | 一种制备动物脱细胞组织基质材料的方法及其制备的组织基质材料 |
CN103418001B (zh) * | 2013-08-26 | 2016-01-20 | 北京瑞健高科生物科技有限公司 | 一种动物组织材料的消毒灭菌方法以及相应的动物组织浸泡溶液 |
CN103520773B (zh) * | 2013-10-24 | 2015-07-01 | 北京积水潭医院 | 一种用于皮肤移植脱细胞真皮材料的制备方法 |
CN104107456B (zh) * | 2014-07-09 | 2016-05-25 | 四川大学 | 无抗原胶原聚集体及其制备方法 |
CN105169483B (zh) * | 2015-10-20 | 2018-10-12 | 中山大学 | 一种脱细胞基质凝胶的制备方法及其脱细胞基质凝胶 |
-
2015
- 2015-12-25 CN CN201510986265.8A patent/CN106913907B/zh active Active
-
2016
- 2016-12-24 PL PL16877807T patent/PL3369439T3/pl unknown
- 2016-12-24 ES ES16877807T patent/ES2763799T3/es active Active
- 2016-12-24 US US16/064,798 patent/US10814037B2/en active Active
- 2016-12-24 JP JP2018530120A patent/JP6663012B2/ja active Active
- 2016-12-24 WO PCT/CN2016/111926 patent/WO2017107997A1/zh active Application Filing
- 2016-12-24 HU HUE16877807A patent/HUE048391T2/hu unknown
- 2016-12-24 PT PT168778074T patent/PT3369439T/pt unknown
- 2016-12-24 EP EP16877807.4A patent/EP3369439B1/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN106913907B (zh) | 2022-04-05 |
US20180369450A1 (en) | 2018-12-27 |
ES2763799T3 (es) | 2020-06-01 |
HUE048391T2 (hu) | 2020-07-28 |
PL3369439T3 (pl) | 2020-04-30 |
US10814037B2 (en) | 2020-10-27 |
PT3369439T (pt) | 2020-01-09 |
EP3369439B1 (en) | 2019-10-16 |
EP3369439A4 (en) | 2018-12-12 |
CN106913907A (zh) | 2017-07-04 |
WO2017107997A1 (zh) | 2017-06-29 |
JP2018537982A (ja) | 2018-12-27 |
EP3369439A1 (en) | 2018-09-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6663012B2 (ja) | 構造記憶特性を有する細胞増殖用足場の製造方法 | |
CN102961777B (zh) | 改性纳米纤维素多孔复合型高吸渗止血敷料的制备方法 | |
CN101366978B (zh) | 可注射用的微粒组织充填材料及其制备方法 | |
CN108478868B (zh) | 可注射型同种异体脂肪脱细胞基质微粒的制备方法及应用 | |
CN107551324B (zh) | 一种可缝合硬膜修补材料的制备及其应用 | |
CN107551312B (zh) | 一种絮状胶原止血纤维及其制备方法 | |
CN106492284B (zh) | 一种生物可降解充填材料的制备方法及其产品和应用 | |
KR102232847B1 (ko) | 섬유화 무세포 진피 기질 및 생체적합성 고분자를 포함하는 조성물 및 이의 제조 방법 | |
CN108261565B (zh) | 一种疝补片、制备方法及其在疝修补中的应用 | |
CN114949359A (zh) | 一种脱细胞基质微粒填充剂及其制备方法 | |
JP6893910B2 (ja) | 構造記憶特性を有する細胞増殖用足場 | |
CN115245597A (zh) | 交联透明质酸凝胶与脱细胞基质微粒组合物 | |
CN114206405B (zh) | 包括脂肪组织源细胞外基质的医疗用组合物及其制造方法 | |
JP7467509B2 (ja) | アスコルビン酸を含有する注入可能な水性インプラント製剤 | |
CN1310946C (zh) | 注射性胶原蛋白的制备方法及其产品 | |
CN114288463B (zh) | 一种流体胶原蛋白止血材料的研制方法 | |
KR102416861B1 (ko) | 연골 성분을 함유하는 연골 재생용 조성물 및 그 제조방법 | |
CN109646718B (zh) | 用于微整形的再生组织基质组合物、制备及应用 | |
CN109513044B (zh) | 用于微整形的再生组织基质微粒植入剂、制备方法及应用 | |
CN111671974A (zh) | 一种吸水诱导形状记忆性的脱细胞真皮基质组织填充物及其制备方法 | |
CN113144277A (zh) | 一种可注射流体明胶及其制备方法和应用 | |
CN114340686B (zh) | 含有软骨成分的软骨再生用组合物及其制备方法 | |
CN112717205B (zh) | 一种利用动物源生物膜制备的口腔修复膜及其制备方法 | |
CN114146224A (zh) | 一种脱细胞真皮基质微粒的制备方法 | |
CN114618008A (zh) | 一种医用丝素蛋白胶原制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180608 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180608 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20190422 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190508 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190725 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20191023 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200107 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200121 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200213 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6663012 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |